Towanna Enoch, NP
Adult Health · Columbia, SCNPI 1982709069
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 95.9% of the total across 258 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 12 manufacturers reported payments, led by Viiv Healthcare Company at 32.0% of the total. 2025 is the largest year on record at $1,975, more than ten times the $61 reported in 2021.
Across 258 payments — averaging $20.36 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Viiv Healthcare Company$2K
- Gilead$1K
- Teva Pharmaceuticals USA, Inc.$463
- Neurocrine Biosciences, Inc.$446
- Johnson & Johnson$391
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$270
- plus $705 from 6 others
What the payments were for
- Food & beverage$5,03996%
- Education$2134%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Viiv Healthcare Company | 74 | $1,681 |
| Gilead | 43 | $1,297 |
| Teva Pharmaceuticals USA, Inc. | 25 | $463 |
| Neurocrine Biosciences, Inc. | 36 | $446 |
| Johnson & Johnson | 11 | $391 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 9 | $270 |
| Otsuka America Pharmaceutical, Inc. | 16 | $214 |
| Alkermes, Inc. | 12 | $184 |
| AbbVie | 22 | $146 |
| Merck | 8 | $132 |
| Vanda Pharmaceuticals Inc. | 1 | $16 |
| Lundbeck LLC | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$5,252 in reported general payments places this provider in the 85th percentile of 292 adult health providers in South Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Invega SustennaPaliperidone Palmitate | 125 | $386,569 |
| Abilify MaintenaAripiprazole | 106 | $303,112 |
| AristadaAripiprazole Lauroxil | 39 | $124,120 |
| IngrezzaValbenazine Tosylate | 11 | $89,588 |
| DescovyEmtricitabine/Tenofov Alafenam | 13 | $26,326 |
| Haloperidol Decanoate | 88 | $6,908 |
| TrintellixVortioxetine Hydrobromide | 14 | $6,773 |
| Divalproex Sodium ErDivalproex Sodium | 55 | $4,077 |
| Quetiapine Fumarate | 134 | $2,787 |
| Fluphenazine Decanoate | 18 | $2,186 |
| Lurasidone Hcl | 12 | $2,180 |
| Fluphenazine Hcl | 11 | $1,793 |
| Oxcarbazepine | 20 | $1,165 |
| Benztropine Mesylate | 80 | $1,052 |
| Aripiprazole | 67 | $875 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonInvega Sustenna | $391 | $386,569125 claims |
| Otsuka America Pharmaceutical, Inc.Abilify Maintena | $214 | $303,112106 claims |
| Alkermes, Inc.Aristada | $184 | $124,12039 claims |
| Neurocrine Biosciences, Inc.Ingrezza | $446 | $89,58811 claims |
| GileadDescovy | $1,297 | $26,32613 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 292 adult health providers in South Carolina.
Other adult health in Columbia
- Kelsey DardenColumbia$7K
- Joanne TurnerColumbia$4K
- Karen RobertsonGreenville$69K
- Christine FranzeseTega Cay$30K
- Jessica RiceGreenville$15K
- Michelle PriceCharleston$13K
- Melissa McCarterSpartanburg$12K
- Andrea OlsonWest Columbia$12K
- Jennifer BrittIrmo$11K
- Nichole SnowSpartanburg$10K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.